Skip to main content
Press Releases

Cidara Therapeutics to Host Investor Day on April 6, 2017

By March 29, 2017No Comments

SAN DIEGO, March 29, 2017 — Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m. PDT) in New York City. Jeffrey Stein, Ph.D., president and chief executive officer, and other members of the Cidara management team, will provide a comprehensive corporate update. In addition, notable infectious disease experts will discuss their perspectives on the anti-infective space.

Interested parties may access a live audio webcast and slides of the presentations on the investor section of Cidara’s website at beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through a Phase 2 study and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit

Robert H. Uhl
Westwicke Partners, LLC
Managing Director
(858) 356-5932

Christy Curran 
Sam Brown Inc.
(615) 414-8668

Primary Logo